Crescent Biopharma, Inc..
CBIO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Crescent Biopharma, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics to address unmet medical needs. The company's pipeline includes product candidates targeting various diseases. Crescent Biopharma likely engages in activities suc...Show More
Better Health for All
0
Crescent Biopharma is a biopharmaceutical company focused on developing novel therapeutics for severe diseases, including various cancers (solid tumors, Acute Myelocytic Leukemia, Multiple Myeloma) and COVID-19 Pneumonia.
1
All its pipeline products are in clinical development (Phase 1/2) and are designed to provide exceptional health benefits, with the entire business devoted to health improvement.
2
As the company is in the development stage and reports a net loss of $24.6 million for Q3 2025, it has no revenue from commercialized products, thus no revenue from harmful products.
3
The company offers professional development, resources, mentorship, and growth opportunities for its healthcare workforce.
4
It provides links to external resources such as the National Cancer Institute and American Cancer Society for healthcare education.
5
Crescent Biopharma is an Equal Opportunity Employer committed to a diverse, inclusive, and equitable workplace, basing employment decisions on qualifications and merit without regard to protected status.
6
The company is sponsoring clinical trials, including those involving novel therapies, and has INDs cleared by the U.S. FDA and approved by China's NMPA.
7
The ASCEND global clinical trial for CR-001 is planned to enroll up to 290 participants, including both treatment-naïve and previously treated patients with multiple solid tumor types, indicating a focus on cancer patients.
8
Fair Money & Economic Opportunity
0
No evidence available to assess Crescent Biopharma, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No regulatory actions, violations, fines, or compliance issues are mentioned for Crescent Biopharma across the provided articles, indicating no public record of labor-law breaches.
1
Fair Trade & Ethical Sourcing
0
No evidence available to assess Crescent Biopharma, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Crescent Biopharma, Inc. on Honest & Fair Business.
Kind to Animals
0
No specific, concrete data points were found in the provided articles regarding Crescent Biopharma, Inc.'s performance on any of the 'Kind to Animals' KPIs. The articles discuss general industry trends, FDA policies, or other companies, but do not provide evidence for CBIO.US's cruelty-free certifications, alternative testing usage, humane certifications, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, animal testing policy, animal testing volume, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.
1
No War, No Weapons
0
No evidence available to assess Crescent Biopharma, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific quantitative data was found in the provided articles to assess Crescent Biopharma against the Planet-Friendly Business KPIs. While one article mentioned "GHG Emissions" and "Waste" as negative impact categories with associated ESG scores, these were not concrete, quantitative metrics (e.g., tCO₂e or waste diversion percentages) that could be mapped to the rubric's thresholds.
1
Therefore, all KPIs are omitted due to lack of specific evidence.
Respect for Cultures & Communities
0
Crescent Biopharma provides a whistleblower hotline for reporting violations of its code of conduct, which covers ethical behavior and compliance.
1
This mechanism is available company-wide via a dedicated website and phone number.
2
Safe & Smart Tech
0
The company is subject to regulatory requirements by the SEC, FDA, and other regulatory agencies, and is required to comply with cGMPs and GCPs.
1
Its Code of Conduct and Ethics, effective June 13, 2025, states a commitment to compliance with all applicable laws, rules, and regulations governing the pharmaceutical and biotechnology industries.
2
Crescent Biopharma collects personally identifiable information (PII) only when voluntarily submitted and uses it to respond to requests, improve services, and for internal purposes.
3
It collects non-PII in aggregate form to understand website usage.
4
The company states it will not sell or rent PII to any third party, and third parties providing support services are prohibited from using information for their own marketing.
5
Zero Waste & Sustainable Products
0
The provided articles discuss the broader biopharma industry's challenges with single-use plastic waste and a recycling program initiated by MilliporeSigma, which has recycled over 4,600 tons of SUT plastic since 2015.
1
They note that biopharma single-use plastics are often biohazardous and difficult to recycle, with an estimated 30,000 tons generated annually, projected to exceed 300,000 tons by 2030.
2
However, neither article provides any specific data, actions, or initiatives directly attributable to Crescent Biopharma, Inc. (CBIO.US) regarding its waste management, product design, packaging, or any other relevant KPIs for Zero Waste & Sustainable Products.